Trial Profile
A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06651600 WITH A PARTIALLY BLINDED EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF PF-06651600 AND PF-06700841 IN SUBJECTS WITH ACTIVE NON-SEGMENTAL VITILIGO
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Mar 2024
Price :
$35
*
At a glance
- Drugs Brepocitinib (Primary) ; Ritlecitinib (Primary)
- Indications Vitiligo
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 04 Mar 2024 According to an Incyte Corporation media release, company will host an in-person analyst and investor event on Monday, March 11, 2024, from 9:00-10:30 a.m. PT (12:00-1:30 p.m. ET) to discuss the key data presentations at AAD.
- 04 Mar 2024 According to an Incyte Corporation media release, data from this study will be presented at the upcoming 2024 American Academy of Dermatology (AAD) Annual Meeting, held March 8-12, 2024, in San Diego and will be published online via the Journal of the American Academy of Dermatology (JAAD) supplement in Fall 2024.
- 28 Sep 2023 Results from sub study, evaluating effects of ritlecitinib on skin and blood biomarkers in participants with non-segmental vitiligo , published in the Journal of Allergy and Clinical Immunology